In terms of the antitumor mechanism of CD39 antibodies, it has been indicated that CD39 blockade on macrophages and monocytes led to the activation of the NALP3 inflammasome and the release of IL-18 and IL-1β to exert anti-tumor effects 15. The gene discussed is ENTPD1; the disease is neoplasm.